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Abstract 
Both neurotoxin II (NT II from venom of Naja naja oxiana) and 20-30 kDa proteins partially purified from pig brain (NTlm) cross-reacting with 
antibodies to NT II were cytotoxic for L929 and KS62 tumor cells at concentrations of 10-6~10-8 M. Modification of Cys residues ignificantly reduced 
cytotoxicity of NT II. Both NT2 and NTlm induced apoptosis in L929 and K562 cells. 
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1. Introduction 
The involvement of neurotrophic substances in cyto- 
toxic cell-mediated immunity was demonstrated. Sub- 
stance P [l], as well as opioid peptides [2], were shown 
to regulate the activity of cytotoxic cells. At the same 
time, cytotoxic proteins were shown to be localized in 
nerve tissue [3]. The involvement of these proteins in 
CNS-mediated processes is supported by the fact that 
behavioral [4,5], as well as electrophysiological [4,6] and 
neuroendocrine [4] actions, were demonstrated for TNF, 
LT, IL-l. These data have allowed us to propose the 
involvement of brain-derived proteins in tumor lysis as 
well as the direct regulation of CNS-mediated processes 
by cytotoxic proteins. 
2. Materials and methods 
2.1. Target cells culturing and cytotoxicity determination 
L929 and KS62 cells culturing and determination of cytotoxic activity 
was performed according to [7]. DNA fragmentation was determined 
as described [8]. 
2.2. Purification of NTlm 
Pig brain tissue was homogenized in 50 mM Tris-HCl (pH 7.4), the 
pellet was removed and supernatant was subjected to size exclusion 
chromatography on a HW-50 column. The fraction containing NT 
II-like immunreactivity (proteins with M, 20-30 kDa) was subjected to 
chromatography on CM-Toyopearl (Fig. 1). SDS-PAGE and im- 
*Corresponding author. 
Abbreviations; NT II, neurotoxin II; NTlm, Neurotoxin-like material; 
TNF, tumor necrosis factor; CNS, central nervous system; SIRS, solu- 
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munoblotting with antibodies to NT II was performed according to 
[9,10]. NT II was carboxymethylated with iodoacetate after reduction 
with dithiothreitol as described [1 11. 
3. Results 
Using antibodies to NT II we demonstrated the pres- 
ence of NTlm in brain tissue. Two stages of chromato- 
graphic separation of the proteins of brain extract al- 
lowed us to obtain fractions that reacted specifically with 
antibodies to NT II (Fig. 1). The presence of several 
immunoreactive proteins with M, of 20-30 kDa was 
detected (not shown). We proposed that NTlm would be 
cytotoxic to transformed cells, so we determined the cy- 
totoxic activity of the fractions, obtained after chromat- 
ographic separation, on L929 tumor cells. The maxima 
of cytotoxic activity correlated with zones of NT-like 
immunoreactivity detected by dot-blot analysis (Fig. 1). 
To determine whether NT II is also cytotoxic for trans- 
formed cells we compared the cytotoxic activity of 
NT i1 and NTlm against L929 and K562 cell lines. Both 
NT II and NTlm were cytotoxic for L929 and KS62 
tumor cells (Fig. 2A,B). NT II was cytotoxic for both 
tumor lines at a concentration of 10e7 M. Modification 
of the Cys residues of NT II significantly reduced NT II 
cytotoxicity (Fig. 2A), since the conformation of NT II 
turned out to be essential for its cytotoxicity. K562 and 
L929 cells differed in their sensitivity to NTlm-mediated 
cytolysis: NTlm was cytotoxic at a concentration of 
1O-7-1O-s M for L929 cells at a concentration of 10m6- 
10e7 M for K562 cells (Fig. 2A,B). To determine whether 
the mechanism of target cell cytolysis is specific, we stud- 
ied the ability of NT II and NTlm to induce DNA frag- 
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Fig. 1. Chromatographic separation of NTlm on CM-Toyopearl. The 
column was equilibrated with 20 mM ammonium acetate, pH 5.5. The 
proteins were eluted by a NaCl gradient (G-1 M). Fractions: (-) 
reacting with antibodies to NT II; (- - -) cytotoxicity. 
mentation in target cells. Fig. 2C shows that both NT2 
and NTlm induced apoptosis in L929 and K562 (not 
shown) cells. 
4. Discussion 
Endogeneous analogues of neurotoxins from snake 
venom have been shown to present in the class of Mam- 
malia. Entothelins, the endogeneous analogues of sara- 
photoxins (carditoxins inducing smooth muscle cells 
concentration), are distributed widely in different tissues 
of mammals and display a wide spectrum of biological 
activities [12]. SIRS was demonstrated to have 80% ho- 
mology with the N-terminal amino acid sequence of 
short neurotoxins from snake venom. SIRS has a it4, of 
10 kDa and is produced mainly by CDS’ supressor T- 
lymphocytes. This protein inhibits cytotoxic activity of 
cytolytic lymphocytes, and induces proliferation of nor- 
mal and transformed cells [ 131. The immunoregulatory 
activity of SIRS is similar to the activity of proteins of 
TGF/? family. The conformation of neurotoxin mole- 
cules (rigid structure with several disulfide bonds) is sim- 
ilar in conformation to the proteins of TGFB family. 
Cytotoxic activity (in particular, ability to induce apop- 
tosis in transformed cells) was demonstrated for TGFB 
[ 14,151. Specific localization of NT-like immunoreactiv- 
ity in brain structures turned out to be analogous to 
distribution of TGFB2 [16]. 
We have detected NTlm in brain tissue. The presence 
of immunoreactivity was demonstrated in several brain 
structures: in cerebellum (Purkinje cells), cerebral cortex, 
olfactory bulb, red nucleus, reticular formation. Localiz- 
ation of NTlp correlates with distribution of GABA- 
ergic neurones. We have demonstrated that NT II and 
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Fig. 2. Cytotoxic activity of NT II (1) and NTlp (2), and carboxymeth- 
ylated NT II (3) against L929 (A) and K562 (B) cek (C) DNA frag- 
mentation induced by NT II and NTlm in L929 cells: lane 1,1 Pst M,., 
standards; lane 2, TNF; lane 3, II Pst M, standards; lane 4, untreated 
cells; lane 5, NT II (0.001 mg/ml); lane 6, NThn (0.001 mg/ml). 
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NTlm are cytotoxic for tumor cells. The cytotoxicity of 
both substances against the L929 cell line was compara- 
ble with TNF (lo-’ M, not shown). Their action was 
highly specific with respect o both target specificity and 
ability to induce apoptosis. Modification of NT II results 
in a decrease in its activity, so rigid conformation of the 
toxin is essential for cytotoxicity. Based on these data we 
propose that NTlm is involved both in elimination of 
tumor cells and CNS-mediated processes. Further study 
of the mechanisms of neuroregulation and cytotoxic ac- 
tion of NTlm will be useful for establishing the principles 
of direct interactions between nervous and immune sys- 
tems. 
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